Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, Global Outlook and Forecast 2024-2031

Report ID: 1068435 | Published Date: Jan 2025 | No. of Page: 65 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Overall Market Size
    2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size: 2021 VS 2028
    2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players in Global Market
    3.2 Top Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies Ranked by Revenue
    3.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Companies
    3.4 Top 3 and Top 5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players in Global Market
        3.6.1 List of Global Tier 1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies
        3.6.2 List of Global Tier 2 and Tier 3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Markets, 2021 & 2028
        4.1.2 Transthyretin Stabilizers
        4.1.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
        4.1.4 RNAi Therapy
        4.1.5 Others
    4.2 By Type - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue & Forecasts
        4.2.1 By Type - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2022
        4.2.2 By Type - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2023-2028
        4.2.3 By Type - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2021 & 2028
        5.1.2 Hereditary Transthyretin Amyloidosis (hATTR)
        5.1.3 Wild Type Transthyretin Amyloidosis (wtATTR)
    5.2 By Application - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue & Forecasts
        5.2.1 By Application - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2022
        5.2.2 By Application - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2023-2028
        5.2.3 By Application - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2021 & 2028
    6.2 By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue & Forecasts
        6.2.1 By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2022
        6.2.2 By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2023-2028
        6.2.3 By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2028
        6.3.2 US Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.3.3 Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.3.4 Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2028
        6.4.2 Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.4.3 France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.4.4 U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.4.5 Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.4.6 Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.4.7 Nordic Countries Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.4.8 Benelux Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2028
        6.5.2 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.5.3 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.5.4 South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.5.5 Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.5.6 India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2028
        6.6.2 Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.6.3 Argentina Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2028
        6.7.2 Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.7.3 Israel Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.7.4 Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
        6.7.5 UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, 2017-2028
7 Players Profiles
    7.1 Pfizer Inc
        7.1.1 Pfizer Inc Corporate Summary
        7.1.2 Pfizer Inc Business Overview
        7.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.1.4 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.1.5 Pfizer Inc Key News
    7.2 GlaxoSmithKline Plc
        7.2.1 GlaxoSmithKline Plc Corporate Summary
        7.2.2 GlaxoSmithKline Plc Business Overview
        7.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.2.4 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.2.5 GlaxoSmithKline Plc Key News
    7.3 Eidos Therapeutics
        7.3.1 Eidos Therapeutics Corporate Summary
        7.3.2 Eidos Therapeutics Business Overview
        7.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.3.4 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.3.5 Eidos Therapeutics Key News
    7.4 Ionis Pharmaceuticals, Inc
        7.4.1 Ionis Pharmaceuticals, Inc Corporate Summary
        7.4.2 Ionis Pharmaceuticals, Inc Business Overview
        7.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.4.4 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.4.5 Ionis Pharmaceuticals, Inc Key News
    7.5 Alnylam Pharmaceuticals
        7.5.1 Alnylam Pharmaceuticals Corporate Summary
        7.5.2 Alnylam Pharmaceuticals Business Overview
        7.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.5.4 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.5.5 Alnylam Pharmaceuticals Key News
    7.6 Prothena Corporation Plc
        7.6.1 Prothena Corporation Plc Corporate Summary
        7.6.2 Prothena Corporation Plc Business Overview
        7.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.6.4 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.6.5 Prothena Corporation Plc Key News
    7.7 Intellia Therapeutics, Inc
        7.7.1 Intellia Therapeutics, Inc Corporate Summary
        7.7.2 Intellia Therapeutics, Inc Business Overview
        7.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.7.4 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.7.5 Intellia Therapeutics, Inc Key News
    7.8 Corino Therapeutics, Inc
        7.8.1 Corino Therapeutics, Inc Corporate Summary
        7.8.2 Corino Therapeutics, Inc Business Overview
        7.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Major Product Offerings
        7.8.4 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global Market (2017-2022)
        7.8.5 Corino Therapeutics, Inc Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Opportunities & Trends in Global Market
    Table 2. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers in Global Market
    Table 3. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints in Global Market
    Table 4. Key Players of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment in Global Market
    Table 5. Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Type
    Table 9. List of Global Tier 1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2023-2028
    Table 30. Pfizer Inc Corporate Summary
    Table 31. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 32. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
    Table 33. GlaxoSmithKline Plc Corporate Summary
    Table 34. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 35. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
    Table 36. Eidos Therapeutics Corporate Summary
    Table 37. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 38. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
    Table 39. Ionis Pharmaceuticals, Inc Corporate Summary
    Table 40. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 41. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
    Table 42. Alnylam Pharmaceuticals Corporate Summary
    Table 43. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 44. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
    Table 45. Prothena Corporation Plc Corporate Summary
    Table 46. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 47. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
    Table 48. Intellia Therapeutics, Inc Corporate Summary
    Table 49. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 50. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
    Table 51. Corino Therapeutics, Inc Corporate Summary
    Table 52. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offerings
    Table 53. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Type in 2021
    Figure 2. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Application in 2021
    Figure 3. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2021
    Figure 8. By Type - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 12. US Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 16. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 17. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 24. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 28. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 30. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share, 2017-2028
    Figure 33. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue, (US$, Mn), 2017-2028
    Figure 37. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
65
Frequently Asked Questions
Transthyretin amyloid cardiomyopathy Treatment Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Transthyretin amyloid cardiomyopathy Treatment Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Transthyretin amyloid cardiomyopathy Treatment Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports